Vaccinex announces first patient dosed with SRF114

Vaccinex (VCNX) announced that its licensee, Surface Oncology (SURF) dosed the first patient in its Phase 1/2 clinical study investigating SRF114, an antibody discovered using Vaccinex’s ActivMAb antibody discovery platform and licensed to Surface Oncology in 2021. "We are very pleased that Surface has progressed SRF114 into a Phase 1/2 clinical study. Advancing this promising drug candidate into the clinic provides positive validation of our proprietary ActivMAb antibody discovery platform," said Ernest Smith, PhD, Chief Scientific Officer of Vaccinex. "ActivMAb is particularly focused on antibody targets like CCR8, a complex GPCR protein. We are gratified that we were able to provide Surface Oncology with a potential best-in-class anti-CCR8 antibody and look forward to continued progress for the SRF114 program."